about
Pharmacogenomics and cardiovascular diseasePharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumonA novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settingsThe effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumonA systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.Genotype-guided coumarin dosing: where are we now and where do we need to go next?Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands.Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation.Discontinuation of anticoagulant care during admission to a psychiatric hospital.Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials.The effect of CYP2C9, VKORC1 and CYP4F2 polymorphism and of clinical factors on warfarin dosage during initiation and long-term treatment after heart valve surgery.Long-term anticoagulant effects ofCYP2C9andVKORC1genotypes in phenprocoumon usersLong-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users
P2860
Q26997380-0349C15C-A45F-47C3-BC4C-5207F33CB724Q27006860-C5B66049-C8D2-481F-A2C5-0C0F0065386BQ33921846-EBD8FF32-A804-4D40-AA56-1BEC9D24E558Q34604533-32EB8C02-DE96-40CE-9376-892E0828529AQ36468182-3DB8F4F2-9788-4AC1-8E93-61CBE8CE0B2AQ37770117-E76269B1-1FCD-4B4F-A515-B0645CE20114Q37908891-D5EAD4C5-8873-4691-9FC0-34077FFF35CDQ38042441-FA3F440A-1C5E-4CF8-A4FF-98B8778AC2D6Q38321269-A324C7E7-9712-49B4-8178-6FD9F976AAB9Q39703517-D299BFF3-E656-4AF5-A522-71305B623964Q41535294-88EAF7B9-6B5B-49FD-996A-C51C705F2E8BQ44784933-321C7544-5188-48EC-AD24-FB77260DADDCQ45023024-CB189C4F-4CC2-4FFF-903E-36B61B3F9810Q50978962-25FABEE6-2113-46DE-8880-848B216EA9CAQ50991074-46D3C67C-C58C-40E7-9B75-D0BA49959466Q57302665-FB9AE1E0-8AA8-4659-9531-7E09715CC6BCQ57302667-CF807CB2-A80B-40BD-85DB-7132C9189E99
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenetics of oral anticoagulant therapy.
@en
Pharmacogenetics of oral anticoagulant therapy.
@nl
type
label
Pharmacogenetics of oral anticoagulant therapy.
@en
Pharmacogenetics of oral anticoagulant therapy.
@nl
prefLabel
Pharmacogenetics of oral anticoagulant therapy.
@en
Pharmacogenetics of oral anticoagulant therapy.
@nl
P1476
Pharmacogenetics of oral anticoagulant therapy.
@en
P2093
Anthonius de Boer
Tom Schalekamp
P304
P356
10.2174/138161210790112737
P577
2010-01-01T00:00:00Z